Status:
COMPLETED
Relation of Metabolic Rate of Omeprazole and Eradication of Helicobacter Pylori Infection
Lead Sponsor:
National Taiwan University Hospital
Collaborating Sponsors:
National Science and Technology Council, Taiwan
Conditions:
Duodenal Ulcer
Helicobacter Pylori Infection
Eligibility:
All Genders
20-75 years
Phase:
PHASE4
Brief Summary
The aims of this study are (1) to evaluate the prevalence rate of PM of CYP2C19 in our country; (2) to evaluate the efficacy of dual therapy with different dose of omeprazole and amoxicillin; (3) to j...
Detailed Description
Anti-H. pylori therapy is now recommended in patients with peptic ulcer disease associated with bacterial infection. Dual therapy containing one PPI and amoxicillin has been suggested to be a better t...
Eligibility Criteria
Inclusion
- Male and female dyspeptic patients with H. pylori-positive duodenal ulcer.
Exclusion
- Pregnant or nursing woman
- Serious concomitant illness
- Malignant tumor of any kind
- Serious bleeding during the course of this ulcer
- Previous gastric surgery
- Taking bismuth compounds, proton pump inhibitors, antibiotic or non-steroid anti-inflammatory drugs for at least one month prior to pretreatment endoscopy.
Key Trial Info
Start Date :
August 1 1996
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 1998
Estimated Enrollment :
128 Patients enrolled
Trial Details
Trial ID
NCT00854451
Start Date
August 1 1996
End Date
February 1 1998
Last Update
March 3 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Internal Medicine, National Taiwan University Hospital
Taipei, Taiwan, 10043